DDInter542 DDInter220
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.[A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients. In March 2018, it was approved under the FDA’s accelerated approval program for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. Full approval for this indication was granted in June 2023.[L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Blinatumomab
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Blinatumomab
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Calaspargase pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Blinatumomab
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Asparaginase Erwinia chrysanthemi {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Blinatumomab
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Theophylline
Theophylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Blinatumomab
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Blinatumomab
Dicoumarol {u} (Compound) binds {v} (Gene) CRYZ
CRYZ {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Blinatumomab
Dicoumarol {u} (Compound) binds {v} (Gene) CRYZ
CRYZ {u} (Gene) is downregulated by {v} (Compound) Bupropion
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Blinatumomab
Dicoumarol {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Tramadol
Tramadol {u} may lead to a major life threatening interaction when taken with {v} Blinatumomab
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Blinatumomab
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Theophylline (Compound) and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Dicoumarol (Compound) binds CRYZ (Gene) and CRYZ (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Dicoumarol (Compound) binds CRYZ (Gene) and CRYZ (Gene) is downregulated by Bupropion (Compound) and Bupropion may lead to a major life threatening interaction when taken with Blinatumomab
Dicoumarol (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Tramadol (Compound) and Tramadol may lead to a major life threatening interaction when taken with Blinatumomab
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab